LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Tectonic Therapeutic today and set a price target of $88.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Tectonic Therapeutic’s promising outlook. The company is making significant progress with its lead program, TX45, which is actively enrolling patients in its Phase 2 APEX trial. This trial targets pulmonary hypertension patients with heart failure with preserved ejection fraction, and it is already more than halfway enrolled, with topline data expected by 2026.
Additionally, Tectonic Therapeutic has a strong financial position, ending Q3 with $268.4 million, which is projected to support operations into the fourth quarter of 2028. Despite the uncertainty surrounding AstraZeneca’s AZD3427, the continued listing of the program is seen as a positive sign. These factors, combined with the absence of any major negative updates from AstraZeneca, contribute to the optimistic outlook for Tectonic Therapeutic’s stock.
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Larimar Therapeutics, and Crinetics Pharmaceuticals. According to TipRanks, Jubinville, PhD has an average return of 17.4% and a 54.13% success rate on recommended stocks.
In another report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $85.00 price target.